Drug
What each drug costs, and who covers it.
Coverage, cash prices, and the daily routine each one actually asks of you.
Drug
Foundayo: the oral without a food-and-water clock
Foundayo (orforglipron) was FDA-approved 1 April 2026. It is a daily oral with no food or water timing restrictions. Bridge $50, commercial-plus-card ~$25, or LillyDirect cash often ~$149 at the lowest dose.
ReadDrug
Wegovy pill: oral semaglutide with a morning window
Wegovy pill launched January 2026. Empty stomach, small water, wait before food or other orals. Bridge $50. Cash 4 mg $149 through 31 August 2026, then $199; maintenance often $299.
ReadDrug
Wegovy injection: the weekly pen on the same Bridge list as the pill
Wegovy injection is weekly semaglutide. It is on the Medicare GLP-1 Bridge with the Wegovy pill. It has no empty-stomach swallow. Cash is a NovoCare ladder separate from the pill's August step.
ReadDrug
Zepbound: on Bridge only as KwikPen
Zepbound is tirzepatide. The Medicare GLP-1 Bridge covers the KwikPen presentation only. Commercial, cash, and Part D rules are separate shelves.
ReadDrug
Rybelsus is not a Medicare GLP-1 Bridge drug
Rybelsus is oral semaglutide labeled for type 2 diabetes. It is not on the Bridge list. A diabetes fill belongs on Part D when covered, not on a $50 demonstration claim.
Read
See what your cheapest option is
Answering the questions is free. If the doctor-ready checklist helps, it's $39 once.